NEWS HIGHLIGHTSMedia Articles Related to Transderm Scop (Scopolamine Transdermal)
Nausea and Vomiting
Source: MedicineNet Antiemetics Specialty [2008.04.29]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 4/29/2008
Published Studies Related to Transderm Scop (Scopolamine Transdermal)
Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. [2009.07]
Death rattle is a frequent symptom (25%-50%) in the terminal stage of life, but there is neither standardized treatment nor prospective investigation performed on the effectiveness of anticholinergic drugs. The aim of the present study was to investigate the effectiveness of three different anticholinergic drugs in the treatment of death rattle in the terminal stage of life...
Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. [2009.06]
STUDY OBJECTIVE: To determine the efficacy of transdermal scopolamine in addition to ondansetron in decreasing the incidence of postoperative nausea and vomiting (PONV)... CONCLUSIONS: Transdermal scopolamine in addition to ondansetron benefits patients at high risk for PONV undergoing outpatient plastic surgery for up to 20 hours after surgery.
A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting. [2009.05]
BACKGROUND: Postoperative nausea and vomiting (PONV) are common complications after ambulatory surgery. We sought to determine whether the use of transdermal scopolamine (TDS) in combination with IV ondansetron (OND) is more effective than one alone for reducing PONV in outpatient settings... CONCLUSIONS: TDS + OND reduces PONV compared with OND alone. This is achieved with a reduction in adverse events.
Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults. [2008.08]
Scopolamine-induced deficits in cognitive and motor processes have been widely demonstrated in animals and humans, although the role of acetylcholine in working memory is not as well understood. This study examined the role of acetylcholine neurotransmission in visuospatial short term and working memory using the Groton Maze Learning Test (GMLT)...
The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. [2008.07]
Drug induced cognitive change is generally investigated using small sample sizes. In terms of null hypothesis significance testing (NHST) this can render a meaningful change non-significant, as a result of insufficient power in the statistical model... This methodology overcomes the limitations of comparisons between studies using different tasks, doses and time at which cognitive functions are measured.
Clinical Trials Related to Transderm Scop (Scopolamine Transdermal)
Scopolamine to Treat Depression
This study will examine the antidepressant effects of scopolamine in patients with major
depressive disorder or bipolar disorder. Scopolamine is commonly used to treat motion
sickness and diarrhea, and is sometimes given before anesthesia or during eye examinations.
In preliminary studies, scopolamine has shown strong antidepressant effects when given as an
intravenous (through a vein) infusion. This study will examine its effectiveness when given
through a skin patch and in pill form.
People between 18 and 50 years of age who have major depressive disorder or bipolar disorder
may be eligible for this study. Candidates are screened with a physical exam,
electrocardiogram (EKG), eye exam, blood and urine tests, psychiatric and clinical interviews
and neuropsychological testing.
Participants wear skin patches behind the ear and take pills according to a prescribed
regimen over an 8-week period. Half of the time the medications contain scopolamine and half
of the time they contain an "active" placebo called glycopyrrolate, a drug that produces side
effects similar to those that may be experienced with scopolamine, but that does not go into
the brain.
Participants come to the NIH Clinical Center every 4 to 5 days while taking the medication
and then for two follow-up visits over the next 2 weeks for a physical exam and evaluations
with clinical rating scales. In addition, participants are asked to undergo two sessions of
cognitive testing and to have two positron emission tomography (PET) studies. Those who have
the PET scans also have a magnetic resonance imaging (MRI) scan. Participants can choose to
participate in the rest of the study without doing the PET scan.
PET is a diagnostic imaging tool that uses a radioactive chemical "tracer" to show cellular
activity in specific tissues of the body. For this procedure, a catheter (thin plastic tube)
is placed into an arm vein for injecting the tracer, and a second catheter is inserted into
an artery in the wrist to obtain arterial blood samples during the scan. The patient lies on
the scanner bed, wearing a special mask that is placed over the head to limit movement during
the scan. MRI uses a magnetic field and radio waves to produce pictures of the brain. For
this test, the subject lies on a table that is moved into the scanner (a metal cylinder),
wearing earplugs to muffle the noise of the machine during the scan.
Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies [Recruiting]
|
